Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study

Albert Oriol, Pilar Giraldo, Ioannis Kotsianidis, Catherine Couturier, Robert Olie, Ralf Angermund, Alessandro Corso

Research output: Contribution to journalArticle


Objective: Multiple myeloma remains incurable and retreatment with available therapies is of substantial interest. Methods: This retrospective observational study included data from 35 patients treated initially and at the first relapse with bortezomib-containing regimens. Results: Bortezomib retreatment provided a similar depth and time to response as first-line therapy; however, as could be expected, the duration of response was shorter with retreatment. The tolerability profile was similar with bortezomib as the first- and second-line therapy, with no evidence of cumulative toxicity. Conclusion: These findings support bortezomib retreatment after a treatment-free interval of ≥6 months in patients who achieved at least a partial response to the first-line bortezomib-based therapy.

Original languageEnglish
Pages (from-to)405-409
Number of pages5
Issue number7
Publication statusPublished - Aug 1 2015



  • Bortezomib
  • Efficacy
  • Multiple myeloma
  • Retreatment
  • Safety

ASJC Scopus subject areas

  • Hematology

Cite this